Introduction of Human Mitochondrial DNA (mtDNA) Sequencing
Mitochondria, called "powerhouses of the cell", are vital organelles in human cells. Human mitochondrial DNAs (mtDNA) form double-strand circular molecules that contain about 16,569 DNA base pairs and encode 37 genes (Fig. 1). There are thousands of mtDNA molecules in a single cell, and mtDNA is highly mutable because it is not protected by histones. The mutated mtDNAs coexist with the wide-type ones in a state called heteroplasmy, which has been detected to be associated with a wide range of human diseases, like Autism Spectrum Disorder (ASD), Leber's hereditary optic neuropathy (LHON), breast cancer, Alzheimer's disease, Parkinson's disease and hypertension. Therefore, the mitochondrial genome is a significant object of researches in clinical diagnosis.
CD Genomics has developed panels that specifically captures the entire human mitochondrial DNA genome. These are multiplex PCR based and probe captured based targeted sequencing approaches which could 100% cover the human mitochondrial genome. Employing this panel, customers no longer need to provide purified mtDNA. mtDNA enrichment is achieved by multiplex PCR amplification or probe capture of the mitochondrial genome. The enriched mtDNA is then subjected to library prep and ultra-deep sequencing. CD Genomics provides this technology to help customers research on mitochondrial genome-related diseases.
Figure 1. The circular human mitochondrial genome.
Advantages of Our Human Mitochondrial DNA (mtDNA) Sequencing Service
- Easier access to initial samples: human gDNA, containing both mtDNA and nuclear DNA
- Ultra-deep sequencing: >1000x coverage, with Illumina PE150 platform
- High accuracy: 100% amplicon or probe coverage of all regions of the mitochondrial genome
- Lowest price: which is dependent on the sample-size, please contact us for a quotation
- Fastest turnaround time: 3-4 weeks
Human Mitochondrial DNA (mtDNA) Sequencing Workflow
Service Specifications
Sample Requirements
|
|
Click |
Sequencing Strategies
|
Bioinformatics Analysis Standard human mtDNA sequencing bioinformatics service includes
|
Analysis Pipeline
Deliverables
- The original sequencing data
- Experimental results
- Data analysis report
- Details in Human Mitochondrial DNA (mtDNA) Sequencing for your writing (customization)
Mapping and coverage results of mtDNA sequencing, as well as the display of mtDNA pathological profiles. (Yao et al., 2019)
Reference:
- Yao Y, Nishimura M, Murayama K, et al. A simple method for sequencing the whole human mitochondrial genome directly from samples and its application to genetic testing. Scientific Reports, 2019, 9(1): 17411.
1. Does whole genome sequencing include mitochondrial DNA?
Whole genome sequencing (WGS) inherently encompasses mitochondrial DNA within its scope. This comprehensive sequencing technique involves the extraction and sequencing of both nuclear and mitochondrial DNA. Due to the abundance of mtDNA copies within cells, whole genome sequencing ensures comprehensive coverage of the mitochondrial genome, enabling concurrent analysis with the nuclear genome.
2. What are the methods for sequencing human mitochondrial DNA?
Various methodologies are employed for sequencing human mitochondrial DNA (mtDNA). Common approaches encompass Sanger sequencing, next-generation sequencing platforms (e.g., Illumina sequencing), and long-read sequencing technologies (e.g., Oxford Nanopore Technologies and Pacific Biosciences). Each methodology offers distinct advantages, drawbacks, and applicability, enabling researchers to tailor their selection based on specific research objectives and resource considerations.
A method for multiplexed full-length single-molecule sequencing of the human mitochondrial genome
Journal: Nature Communications
Impact factor: 16.7
Published: 06 October 2022
Background
Mitochondria contain circular genomes with vestigial functions. Heteroplasmy can significantly impact health, requiring accurate variant detection for diagnosis and treatment. Traditional sequencing methods have limitations, but long-read technologies like ONT and PacBio offer improved accuracy. Using Cas9 for targeted enrichment with ONT's Q20+ chemistry enhances read precision and lowers costs, making it suitable for low-quality samples and extending its use in mitochondrial research and clinical applications.
Methods
- Human cell lines
- 15 clinical samples
- DNA quality control
- Long-range PCR
- Circular mtDNA pre-enrichment
- Library preparation
- Long-read nanopore sequencing
- Short-read sequencing
- Pre-processing raw data
- Alignment
- Variant calling
- Annotation of mtDNA variants
- Circos plots
Results
The authors refined the Cas9-mtDNA-enrichment protocol to enable highly selective single-molecule sequencing of mtDNA from human gDNA samples, facilitating multiplexing without additional barcoding steps. This method involves Exonuclease V digestion for mtDNA enrichment, dephosphorylation of gDNA ends, and sequence-specific cleavage by dual-RNA-guided Cas9 endonuclease. This approach generates a barcode at the Cas9 cut site, facilitating library preparation and sequencing. After Cas9 cleavage, samples are treated with Proteinase K to remove bound Cas9 protein, followed by ligation of ONT sequencing adaptors to phosphorylated cleavage sites.
Fig. 1 Cas9-mtDNA-enrichment, barcoding, pooling and demultiplexing approach for long-read sequencing.
Cas9-mtDNA-enrichment analysis accurately detects heteroplasmy in pathogenic SNVs across 14 clinical samples. The method, without Exonuclease V treatment, achieves variable mtDNA genome coverage (×33 to ×2335), correlating with sample DNA degradation levels. Including both full-length reads and reads starting at specific Cas9 cut-site barcodes boosts coverage and confidence in variant calling. All reported heteroplasmies are confirmed, with frequencies ranging from <0.2% to 100%, and no large deletions observed. Additionally, non-pathogenic polymorphic sites and variants of unknown significance are identified, underscoring the importance of assessing variant frequency within the general population and specific haplogroups.
Table 1. Pathogenic SNV identification and heteroplasmy determination in the confirmed clinical samples with mtDNA alterations
Cas9-mtDNA-enrichment analysis successfully identifies multiple mtDNA deletions in a complex clinical case. Using three gRNAs spanning the mitochondrial genome, the method detects two large deletions: m.3264_16070del (7.6% heteroplasmy) and m.10751_14129del (84.1% heteroplasmy), alongside wild-type mtDNA (8.3% frequency). Comparison with lrPCR and Illumina sequencing confirms the benefit of native mtDNA sequencing, overcoming biases and providing more accurate estimates of mtDNA populations.
Fig. 2 Multiple mtDNA deletions in a clinical sample.
Conclusion
This method uses Cas9 nuclease and nanopore sequencing to efficiently target and sequence the full-length human mitochondrial genome. It achieves high coverage, accurately detecting SNVs and multiple deletions in clinical samples. The authors' custom analysis pipeline enables precise variant calling and facilitates comprehensive mtDNA analysis, benefiting molecular diagnosis and population studies. Additionally, it has potential applications in investigating somatic mutations and DNA modifications, extending to animal species for conservation genetics and phylogenetics research.
Reference:
- Keraite I, Becker P, Canevazzi D, et al. A method for multiplexed full-length single-molecule sequencing of the human mitochondrial genome. Nature Communications, 2022, 13(1): 5902.